Show simple item record

dc.contributor.authorWilson, JMen_US
dc.contributor.authorParker, Cen_US
dc.date.accessioned2017-08-14T10:14:42Z
dc.date.issued2016-09en_US
dc.identifier.citationExpert review of anticancer therapy, 2016, 16 (9), pp. 911 - 918en_US
dc.identifier.issn1473-7140en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/769
dc.identifier.eissn1744-8328en_US
dc.identifier.doi10.1080/14737140.2016.1222273en_US
dc.description.abstract<h4>Introduction</h4>A number of drugs have been shown to extend life expectancy in castration-resistant prostate cancer (CRPC). Skeletal related events (SREs) secondary to bone metastases cause significant morbidity for men with CRPC. The α-emitting radiopharmaceutical radium-223 dichloride has been shown to improve overall survival, time to symptomatic skeletal events (SSEs) and quality of life in CRPC.<h4>Areas covered</h4>The development of radium-223 from pre-clinical studies to the evidence of efficacy and safety from a phase 3 trial is discussed as well as its pharmacokinetics and metabolism. The integration of radium-223 into routine care for patients with advanced prostate cancer is included including a comparison with other agents in this setting. Expert commentary: The risk/benefit ratio for radium-223 is very similar to that of other agents used in the CRPC setting and is a treatment option for men unsuitable for cytotoxic chemotherapy because of comorbidities. The ALSYMPCA trial demonstrated an improvement in SSEs with radium-223. This is a clinically relevant end-point as not all radiologically-detected SREs are apparent to patients. The correct sequencing of the life-prolonging treatments available to men with CRPC is subject to debate. Radium-223 therapy should be considered before the development of visceral metastases. Drug-combination studies are underway.en_US
dc.formatPrint-Electronicen_US
dc.format.extent911 - 918en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectAnimalsen_US
dc.subjectHumansen_US
dc.subjectBone Neoplasmsen_US
dc.subjectRadiumen_US
dc.subjectRadioisotopesen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectTreatment Outcomeen_US
dc.subjectSurvival Rateen_US
dc.subjectQuality of Lifeen_US
dc.subjectMaleen_US
dc.subjectProstatic Neoplasms, Castration-Resistanten_US
dc.titleThe safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-08-05en_US
rioxxterms.versionofrecord10.1080/14737140.2016.1222273en_US
rioxxterms.licenseref.startdate2016-09en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfExpert review of anticancer therapyen_US
pubs.issue9en_US
pubs.notes12 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume16en_US
pubs.embargo.terms12 monthsen_US
dc.contributor.icrauthorParker, Chrisen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record